

Effective: July 9, 2024

Guideline Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Non-Formulary <input type="checkbox"/> Step-Therapy <input type="checkbox"/> Administrative
-----------------------	---

<p>Applies to:</p> <p>Commercial Products</p> <p><input checked="" type="checkbox"/> Harvard Pilgrim Health Care Commercial products; Fax: 617-673-0988</p> <p><input checked="" type="checkbox"/> Tufts Health Plan Commercial products; Fax: 617-673-0988 CareLinkSM – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization</p> <p>Public Plans Products</p> <p><input checked="" type="checkbox"/> Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); Fax: 617-673-0988</p>
--

Note: While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to ensure that prior authorization has been obtained.

Overview

Food and Drug Administration – Approved Indications

Bepreve (bepotastine) ophthalmic solution is a histamine H₁ receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.

Clinical Guideline Coverage Criteria

The plan may authorize coverage of **generic bepotastine** when all of the following criteria are met:

1. Trial and failure of TWO alternative medications for the treatment of allergic conjunctivitis symptoms, such as an ophthalmic mast cell stabilizer (i.e., cromolyn, lodoxamide, nedocromil) or an ophthalmic antihistamine (i.e., olopatadine, epinastine, azelastine)

Renewal Authorization for generic bepotastine

1. Patient has shown improvement with therapy

Limitations

1. Duration of approval is limited to 12 months.

Codes

1. For a non-formulary medication request, please refer to the Pharmacy Medical Necessity Guidelines for Formulary Exceptions and submit a formulary exception request to the plan as indicated.

References

1. Bepreve (bepotastine) [prescribing information]. Bridgewater, NJ: Bausch + Lomb; August 2022.

Approval And Revision History

September 2022: Reviewed by the Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

- July 11, 2023: No changes
- July 9, 2024: No changes

Background, Product and Disclaimer Information

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.